Contact Company Product Candidates Technology Platforms Investors News & Media Takeda takeover bid Financial Information Investor Information FINANCIAL INFORMATION SEC fillings Annual reports Interim reports Listing Prospects Other financial Information Grants INVESTOR INFORMATION Financial services Auditor Corporate governance Company Product Candidates Technology Platforms Investors News & Media Takeda takeover bid Contact Careers at TiGenix Terms of Use Privacy Notice © 2017 TiGenix All rights reserved. Disclaimer DISCLAIMER – IMPORTANT THE FOLLOWING WEBPAGES CONTAIN MATERIALS THAT ARE NOT DIRECTED AT OR TO BE ACCESSED BY PERSONS RESIDENT, DOMICILED OR PHYSICALLY PRESENT IN, AND MAY NOT BE DOWNLOADED, FORWARDED, TRANSMITTED OR SHARED WITH ANY OTHER PERSON, DIRECTLY OR INDIRECTLY, EITHER IN WHOLE OR IN PART IN, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA, THE UNITED STATES OF AMERICA AND ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS NOTICE REQUIRES YOU TO CONFIRM AND ACKNOWLEDGE CERTAIN STATEMENTS (INCLUDING THAT YOU ARE NOT RESIDENT, DOMICILED OR PHYSICALLY PRESENT IN ANY SUCH JURISDICTION) BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION ON THIS AREA OF THE WEBSITE. The following webpages contain information and materials relating to the voluntary public takeover bid in cash that Takeda Pharmaceutical Company Ltd. ("Takeda") has launched for TiGenix NV’s ("TiGenix") ordinary shares (the "Shares") and warrants to subscribe for Shares ("Warrants") not yet owned (directly or indirectly) by Takeda and its affiliates in accordance with Belgian law (the "Belgian Offer") and may be consulted exclusively by investors who have access in Belgium to a copy of the Takeda takeover prospectus (including the response memorandum of TiGenix) approved by the FSMA on April 24, 2018 and made public on April 27, 2018 (the "Prospectus") that has been legally distributed in Belgium. The Belgian Offer is only made in Belgium, and no steps have been or shall be made to obtain authorization to distribute the Prospectus in jurisdictions outside Belgium. Reproduction of the electronic version of the Prospectus on another website or at any other location, or its reproduction in printed form with a view to the distribution thereof in any way is expressly forbidden. CONCURRENTLY WITH THE BELGIAN OFFER, THE BIDDER HAS LAUNCHED A TENDER OFFER IN THE UNITED STATES TO HOLDERS OF TIGENIX’S AMERICAN DEPOSITARY SHARES ISSUED BY DEUTSCHE BANK TRUST COMPANY AMERICAS ACTING AS DEPOSITARY (“ADSS”), WHEREVER LOCATED, AND TO HOLDERS OF SHARES WHO ARE RESIDENT IN THE U.S. IN ACCORDANCE WITH APPLICABLE U.S. LAW (THE “U.S. OFFER”). HOLDERS OF ADSS AND SHARES SUBJECT TO THE U.S. OFFER ARE URGED TO READ THE OFFER DOCUMENTS WHICH ARE AVAILABLE AT WWW.SEC.GOV. THE U.S. OFFER IS BEING MADE PURSUANT TO A TENDER OFFER STATEMENT ON SCHEDULE TO FILED BY TAKEDA WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE “SEC”) ON APRIL 30, 2018, AS AMENDED FROM TIME TO TIME. TIGENIX HAS FILED A SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WITH THE SEC WITH RESPECT TO THE U.S. OFFER ON APRIL 30, 2018, AS AMENDED FROM TIME TO TIME. HOLDERS OF ADSS AND SHARES SUBJECT TO THE U.S. OFFER WHO WISH TO PARTICIPATE IN THE U.S. OFFER, ARE URGED TO CAREFULLY REVIEW THE DOCUMENTS RELATING TO THE U.S. OFFER THAT HAVE BEEN FILED BY TAKEDA AND TIGENIX WITH THE SEC SINCE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE U.S. OFFER. YOU MAY OBTAIN A FREE COPY OF THESE DOCUMENTS AND OTHER DOCUMENTS FILED BY TIGENIX AND TAKEDA WITH THE SEC, AT THE SEC’S WEBSITE AT WWW.SEC.GOV. YOU MAY ALSO OBTAIN FREE COPIES OF THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 AND OTHER DOCUMENTS FILED WITH THE SEC BY TIGENIX AT WWW.TIGENIX.COM. THE SCHEDULE TO, INCLUDING THE OFFER TO PURCHASE AND RELATED MATERIALS, AND THE SCHEDULE 14D-9, INCLUDING THE SOLICITATION/RECOMMENDATION STATEMENT, MAY ALSO BE OBTAINED FOR FREE BY CONTACTING GEORGESON LLC, THE INFORMATION AGENT FOR THE TENDER OFFER, AT +1 866 391 6921. IN ADDITION TO THE OFFER AND CERTAIN OTHER TENDER OFFER DOCUMENTS, AS WELL AS THE SOLICITATION/RECOMMENDATION STATEMENT, TIGENIX FILES REPORTS AND OTHER INFORMATION WITH THE SEC. YOU MAY READ AND COPY ANY REPORTS OR OTHER INFORMATION FILED BY TIGENIX AT THE SEC PUBLIC REFERENCE ROOM AT 100 F STREET, N.E., WASHINGTON, D.C. 20549. PLEASE CALL THE SEC AT 1-800-SEC-0330 FOR FURTHER INFORMATION ON THE PUBLIC REFERENCE ROOM. TIGENIX’S FILINGS AT THE SEC ARE ALSO AVAILABLE TO THE PUBLIC FROM COMMERCIAL DOCUMENT-RETRIEVAL SERVICES AND AT THE WEBSITE MAINTAINED BY THE SEC AT WWW.SEC.GOV. This area of the website and the information contained herein are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident, domiciled or physically present in Australia, Canada, Japan, South Africa, the United States or any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction and do not constitute an offer to purchase or the solicitation of an offer to sell, any securities of TiGenix in Australia, Canada, Japan, South Africa, the United States or in any other jurisdiction in which such offer, solicitation, purchase or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. It is your responsibility to inform yourself as to the full observance of any relevant laws and regulatory requirements. If you are not permitted to view materials on this area of the website or are in any doubt as to whether you are permitted to view these materials, please exit this website. Access to electronic versions of these materials is being made available on this website by TiGenix in good faith and for information purposes only. TiGenix reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit this area of the website. In addition, the contents of this area of the website may be amended at any time in whole or in part at the sole discretion of TiGenix. This notice shall be governed by, and interpreted in accordance with, Belgian law. By clicking "I agree" you confirm and certify that (i) you have read and understood the foregoing, (ii) you are a person that is not resident, domiciled or physically present in Canada, Australia, Japan, South Africa or the United States and (iii) you agree not to distribute the Prospectus and any other information on the following webpages directly or indirectly in or into Canada, Australia, Japan, South Africa, the United States or in any other jurisdiction in which such distribution would be prohibited by applicable law, and agree to comply with all of the terms and restrictions set out in this notice. I Agree I Disagree Disclaimer DISCLAIMER – IMPORTANT THE FOLLOWING WEBPAGES CONTAIN MATERIALS THAT ARE NOT DIRECTED AT OR TO BE ACCESSED BY PERSONS RESIDENT, DOMICILED OR PHYSICALLY PRESENT IN, AND MAY NOT BE DOWNLOADED, FORWARDED, TRANSMITTED OR SHARED WITH ANY OTHER PERSON, DIRECTLY OR INDIRECTLY, EITHER IN WHOLE OR IN PART IN, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA, THE UNITED STATES OF AMERICA AND ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS NOTICE REQUIRES YOU TO CONFIRM AND ACKNOWLEDGE CERTAIN STATEMENTS (INCLUDING THAT YOU ARE NOT RESIDENT, DOMICILED OR PHYSICALLY PRESENT IN ANY SUCH JURISDICTION) BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION ON THIS AREA OF THE WEBSITE. The following webpages contain information and materials relating to the voluntary public takeover bid in cash that Takeda Pharmaceutical Company Ltd. ("Takeda") has launched for TiGenix NV’s ("TiGenix") ordinary shares (the "Shares") and warrants to subscribe for Shares ("Warrants") not yet owned (directly or indirectly) by Takeda and its affiliates in accordance with Belgian law (the "Belgian Offer") and may be consulted exclusively by investors who have access in Belgium to a copy of the Takeda takeover prospectus (including the response memorandum of TiGenix) approved by the FSMA on April 24, 2018 and made public on April 27, 2018 (the "Prospectus") that has been legally distributed in Belgium. The Belgian Offer is only made in Belgium, and no steps have been or shall be made to obtain authorization to distribute the Prospectus in jurisdictions outside Belgium. Reproduction of the electronic version of the Prospectus on another website or at any other location, or its reproduction in printed form with a view to the distribution thereof in any way is expressly forbidden. CONCURRENTLY WITH THE BELGIAN OFFER, THE BIDDER HAS LAUNCHED A TENDER OFFER IN THE UNITED STATES TO HOLDERS OF TIGENIX’S AMERICAN DEPOSITARY SHARES ISSUED BY DEUTSCHE BANK TRUST COMPANY AMERICAS ACTING AS DEPOSITARY (“ADSS”), WHEREVER LOCATED, AND TO HOLDERS OF SHARES WHO ARE RESIDENT IN THE U.S. IN ACCORDANCE WITH APPLICABLE U.S. LAW (THE “U.S. OFFER”). HOLDERS OF ADSS AND SHARES SUBJECT TO THE U.S. OFFER ARE URGED TO READ THE OFFER DOCUMENTS WHICH ARE AVAILABLE AT WWW.SEC.GOV. THE U.S. OFFER IS BEING MADE PURSUANT TO A TENDER OFFER STATEMENT ON SCHEDULE TO FILED BY TAKEDA WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE “SEC”) ON APRIL 30, 2018, AS AMENDED FROM TIME TO TIME. TIGENIX HAS FILED A SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WITH THE SEC WITH RESPECT TO THE U.S. OFFER ON APRIL 30, 2018, AS AMENDED FROM TIME TO TIME. HOLDERS OF ADSS AND SHARES SUBJECT TO THE U.S. OFFER WHO WISH TO PARTICIPATE IN THE U.S. OFFER, ARE URGED TO CAREFULLY REVIEW THE DOCUMENTS RELATING TO THE U.S. OFFER THAT HAVE BEEN FILED BY TAKEDA AND TIGENIX WITH THE SEC SINCE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE U.S. OFFER. YOU MAY OBTAIN A FREE COPY OF THESE DOCUMENTS AND OTHER DOCUMENTS FILED BY TIGENIX AND TAKEDA WITH THE SEC, AT THE SEC’S WEBSITE AT WWW.SEC.GOV. YOU MAY ALSO OBTAIN FREE COPIES OF THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 AND OTHER DOCUMENTS FILED WITH THE SEC BY TIGENIX AT WWW.TIGENIX.COM. THE SCHEDULE TO, INCLUDING THE OFFER TO PURCHASE AND RELATED MATERIALS, AND THE SCHEDULE 14D-9, INCLUDING THE SOLICITATION/RECOMMENDATION STATEMENT, MAY ALSO BE OBTAINED FOR FREE BY CONTACTING GEORGESON LLC, THE INFORMATION AGENT FOR THE TENDER OFFER, AT +1 866 391 6921. IN ADDITION TO THE OFFER AND CERTAIN OTHER TENDER OFFER DOCUMENTS, AS WELL AS THE SOLICITATION/RECOMMENDATION STATEMENT, TIGENIX FILES REPORTS AND OTHER INFORMATION WITH THE SEC. YOU MAY READ AND COPY ANY REPORTS OR OTHER INFORMATION FILED BY TIGENIX AT THE SEC PUBLIC REFERENCE ROOM AT 100 F STREET, N.E., WASHINGTON, D.C. 20549. PLEASE CALL THE SEC AT 1-800-SEC-0330 FOR FURTHER INFORMATION ON THE PUBLIC REFERENCE ROOM. TIGENIX’S FILINGS AT THE SEC ARE ALSO AVAILABLE TO THE PUBLIC FROM COMMERCIAL DOCUMENT-RETRIEVAL SERVICES AND AT THE WEBSITE MAINTAINED BY THE SEC AT WWW.SEC.GOV. This area of the website and the information contained herein are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident, domiciled or physically present in Australia, Canada, Japan, South Africa, the United States or any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction and do not constitute an offer to purchase or the solicitation of an offer to sell, any securities of TiGenix in Australia, Canada, Japan, South Africa, the United States or in any other jurisdiction in which such offer, solicitation, purchase or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. It is your responsibility to inform yourself as to the full observance of any relevant laws and regulatory requirements. If you are not permitted to view materials on this area of the website or are in any doubt as to whether you are permitted to view these materials, please exit this website. Access to electronic versions of these materials is being made available on this website by TiGenix in good faith and for information purposes only. TiGenix reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit this area of the website. In addition, the contents of this area of the website may be amended at any time in whole or in part at the sole discretion of TiGenix. This notice shall be governed by, and interpreted in accordance with, Belgian law. By clicking "I agree" you confirm and certify that (i) you have read and understood the foregoing, (ii) you are a person that is not resident, domiciled or physically present in Canada, Australia, Japan, South Africa or the United States and (iii) you agree not to distribute the Prospectus and any other information on the following webpages directly or indirectly in or into Canada, Australia, Japan, South Africa, the United States or in any other jurisdiction in which such distribution would be prohibited by applicable law, and agree to comply with all of the terms and restrictions set out in this notice. I agree I disagree